Trial reportJournal of the American Academy of Child and Adolescent Psychiatry2016
Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder.
Trial report in Journal of the American Academy of Child and Adolescent Psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00080145 (Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder), which is not on this map. Cited by 36 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder
Who cites it
36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Eating cognitions, emotions and behaviour under treatment with second generation antipsychotics: A systematic review and meta-analysis.Journal of psychiatric research · 2023Pooled it
- Correlates of Feeding Difficulties Among Children with Autism Spectrum Disorder: A Systematic Review.Journal of autism and developmental disorders · 2022Pooled it
- Effects of Risperidone in Autistic Children and Young Adults: A Systematic Review and Meta-Analysis.Current neuropharmacology · 2021Pooled it
- Safety and Tolerability of Antipsychotic Medication in Individuals with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis.Paediatric drugs · 2019Pooled it
- A Systematic Review and Meta-analysis of Parent Training for Disruptive Behavior in Children with Autism Spectrum Disorder.Clinical child and family psychology review · 2017Pooled it
- Cannabinoid treatment for autism: a proof-of-concept randomized trial.Molecular autism · 2021Trial
- A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Trial
- No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder.Journal of child and adolescent psychopharmacology · 2016Trial
- Medical treatment of autism spectrum disorder in children: Current evidence, controversies, and clinical challenges.World journal of clinical pediatrics · 2026Article
- Weight status of children and adolescents with autism spectrum disorder: A cross-sectional analysis of primary care electronic medical records and linked health administrative datasets in Ontario, Canada.Pediatric obesity · 2025Article
- Rapid Weight Gain After Pediatric Kidney Transplant and Development of Cardiometabolic Risk Factors Among Children Enrolled in the North American Pediatric Renal Trials and Collaborative Studies Cohort.Pediatric transplantation · 2025Article
- Metabolic Side Effects of Risperidone in Pediatric Patients with Neurological Disorders: A Prospective Cohort Study.Journal of clinical medicine · 2024Article
- Body Composition and Anthropometric Measurements in Children and Adolescents with Autism Spectrum Disorder: A Case-Control Study in Lebanon.Nutrients · 2024Article
- Assessment Methods for Problematic Eating Behaviors in Children and Adolescents With Autism Spectrum Disorder.Journal of the Korean Academy of Child and Adolescent Psychiatry · 2024Article
- Thermoneutral housing does not rescue olanzapine-induced trabecular bone loss in C57BL/6J female mice.Biochimie · 2023Article
- Developmental Regression Followed by Epilepsy and Aggression: A New Syndrome in Autism Spectrum Disorder?Journal of personalized medicine · 2023Article
- Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials.Autism : the international journal of research and practice · 2023Article
- Peripubertal Alterations of Leptin Levels in Patients with Autism Spectrum Disorder and Elevated or Normal Body Weight.International journal of molecular sciences · 2023Article
- Metabolic biomarkers of risperidone-induced weight gain in drug-naïve patients with schizophrenia.Frontiers in psychiatry · 2023Article
- Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.Cannabis and cannabinoid research · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
Abstract
objectiveWe examine weight gain and metabolic consequences of risperidone monotherapy in children with autism spectrum disorder (ASD).
methodThis was a 24-week, multisite, randomized trial of risperidone only versus risperidone plus parent training in 124 children (mean age 6.9 ± 2.35 years; 105 boys and 19 girls) with ASD and serious behavioral problems. We monitored height, weight, waist circumference, and adverse effects during the trial. Fasting blood samples were obtained before treatment and at week 16.
resultsIn 97 children with a mean of 22.9 ± 2.8 weeks of risperidone exposure, there was a 5.4 ± 3.4 kg weight gain over 24 weeks (p < .0001); waist circumference increased from 60.7 ± 10.4 cm to 66.8 ± 11.3 cm (p < .0001). At baseline, 59 of 97 children (60.8%) were classified as having normal weight; by week 24, only 25 of 85 (29.4%) remained in that group. Growth curve analysis showed a significant change in body mass index (BMI) z scores from pretreatment to week 24 (p < .0001). This effect was significantly greater for children with reported increased appetite in the first 8 weeks. From before treatment to week 16, there were significant increases in glucose (p = .02), hemoglobin A1c (p = .01), insulin (p <.0001), homeostatic model assessment-insulin resistance (HOMA-IR; p < .001), alanine aminotransferase (p = .01), and leptin (p < .0001). Adiponectin declined (p = .003). At baseline, 7 children met conventional criteria for metabolic syndrome; by week 16, 12 additional children were so classified.
conclusionRapid weight gain with risperidone treatment may promote the cascade of biochemical indices associated with insulin resistance and metabolic syndrome. Appetite, weight, waist circumference, liver function tests, blood lipids, and glucose warrant monitoring. Clinical trial registration information-Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders; http://clinicaltrials.gov/; NCT00080145.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.